Biotech News

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Sensei Biotherapeutics (SNSE)Sensei Biotherapeutics2026-06-25 13:46 ESTClinical readout

Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports key clinical milestones in endometrial and breast cancer BOSTON --(BUSINESS WIRE)--Mar. 30, 2026-- Sensei Biotherapeutics, Inc.

Open original release

Related news

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SNSESensei Biotherapeutics2026-06-25 13:46 EST

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

View all latest news

Sensei Biotherapeutics

Sensei Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SNSESensei Biotherapeutics2026-06-26 08:46 EST

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

SNSESensei Biotherapeutics2026-06-26 08:46 EST

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

SNSESensei Biotherapeutics2026-06-26 08:46 EST

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

SNSESensei Biotherapeutics2026-06-26 08:46 EST

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

SNSESensei Biotherapeutics2026-06-26 08:46 EST

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Biotechnology
Location: United States